NIH· @NIH · X·· 8 天前AI 评分22
AI 导读
🔬GLP-1药物已改变肥胖和糖尿病治疗的格局。 如今,越来越多的研究表明,它们还可能通过调节大脑的多巴胺奖赏系统以及全身众多其他系统,用于治疗物质使用障碍。 阅读NIDA主任Nora Volkow与Eric Wargo在@ScienceMagazine发表的完整评论 ➡️ https://bit.ly/4emtunN
正文
🔬GLP-1 medications have transformed the landscape of obesity and diabetes treatment.
Now, mounting research suggests they may also be used to treat substance use disorders, by modulating the brain’s dopamine reward system as well as numerous other systems throughout the body.
Read the full commentary from NIDA Director Nora Volkow and Eric Wargo in @ScienceMagazine ➡️ https://bit.ly/4emtunN
来源:NIH · x.com